Clinical Efficacy of Oxycontin Combined with Gabapentin in the Treatment of Neuropathic Cancer Pain and the Effect on the Immune Function of Patients / 现代生物医学进展

Objective:To explore the effect of oxycontin combined with gabapentin on the clinical cure and immunity for patients with neuropathic cancer pain.Methods:80 patients with neuropathic cancer pain were enrolled in our hospital from June to 2016 July,of which patients divided into two groups randomly,Group A(n=40) accepted oxycontin treatment,and Group B (n=40) adopted gabapentin based on the patients in Group A.The VAS score and curative effect of the patients were compared between two groups;The quality of life of all patients were evaluated post-treatment,and the change of immunity indexes were compared and analyzed.Results:The VAS score of all patients was decreased significantly compared with pre-treatment (P＜0.05),and the score of Group B was lower than those patients in Group A (P＜0.05);The total remission rate of Group B was significantly higher than those of Group A (P＜0.05);after treatment,the score of appetite,emotion,sleep,daily activities,social communications of all patients decreased significantly compared with pre-treatment (P＜0.05),and the change of Group B was decrease significantly higher than those patients in Group A (P＜0.05);the immune index of two groups was significantly increased (P＜0.05),and the level of the indexes including IgG,IgA,IgM,CD4+,CD4+/CD8+ and circulating immune complex (CIC) increased compared with pre-treatment remarkably (P＜0.05),and which change in Group B was significantly higher than Group A (P＜0.05).Conclusions:Oxycontin combined with gabapentin for patients with neuropathic cancer pain deserved popularization in clinical,and which not only possessed well clinical effect,but also increased the quality of life.

Efficacy and safety of pregabalin in neuropathic cancer pain: a randomized control multicentre trial / 中华神经医学杂志

Objective To examine the efficacy and safety of pregabalin in patients with neuropathic cancer pain (NCP).Methods A prospective randomized control multicenter trial was conducted in five hospitals;from January 2015 to January 2016,one hundred and twenty two eligible inpatients and outpatients were divided into pregablin treatment group (n=60) and control group (n=62).Patients in the pregablin group added pregablin to opiod background analgesia,while those in the control group raised opioid dose instead.The Numerical Pain Rating Scale (NRS) scores,paraesthesia scale scores,Hamilton's Depression (HAMD) scale scores,analgesia dose,patiends satisfaction,and adverse events were recorded 14 d after each treatment.Results After each treatment,the NRS scores were decreased by (2.3 ±1.1) and (1.3±1.5),the paraesthesia scale scores were decreased by (1.6±0.6) and (0.4±0.3),and the HAMD scale scores were decreased by (4.4±1.2) and (2.4±1.0) in the pregablin treatment group and control group,respectively,with significant differences (P＜0.05).Morphine dose for breakthrough pain in pregabalin group was statistically less than that in control group ([30.6±3.5] mg/d vs.[70.9±12.3] mg/d,P＜0.05).Patients satisfaction in the pregablin treatment group was significantly higher than that in the control group (P＜0.05).Pregabalin treatment group had less severe adverse effects (3/56,5％) as compared with control group (10/59,16.1％,P＜0.05).Conclusion Pregabalin has positive roles in patients with NCP already receiving opioid;pregabalin has better pain-control and mood improvement.

Tashinone II A-sulfoacid-natrum elevates the pain threshold through inhibiting nuclear factor kappa B pathway in neuropathic cancer pain.

OBJECTIVE: The purpose of this study was to evaluate the effects of Tashinone II A-sulfoacid-natrum on the pain threshold and potential molecular mechanism for neuropathic cancer pain. METHODS: Forty‑five male Balb/c mice were divided into control group model group and experiment group with each 15. The sciatic nerve muscle plexus of experiment and model group were given injection containing S180 sarcoma cell 2 × 106 mL for each mouse. Mice in the experiment group were given Tashinone II A-sulfoacid-natrum 25 mg/kg once a day intraperitoneal injection. Moreover, mice in the control group were given physiological saline 25 mg/kg, once a day intraperitoneal injection. The mechanical withdraw threshold and thermal withdraw latency were recorded before S180 sarcoma cell injection and in the time point of day 3, 6, 9, 12, and 14. After 14 days treatment, the mice were treated to death and the sciatic nerve CX3CR1 and nuclear factor kappa B (NF‑κB) mRNA was tested by quantitative polymerase chain reaction. RESULTS: Compared with control group, the mechanical and thermal pain threshold of experiment group was significant decreased (P < 0.05). However, compared with the model group, the mechanical, and thermal pain threshold of experiment group was significant elevated in time point of day 3, 6, 9, 12, 14 for mechanical pain threshold and day 9, 12 14 for thermal pain threshold (P < 0.05); the pain threshold for the experiment and model group was decreased in the first 9 days and then elevated gradually. Compared with control group, the CX3CR1 and NF‑κB mRNA relative expression in mice sciatic nerve of experiment group was significant elevated (P < 0.05); but compared with model group, the CX3CR1 and NF‑κB mRNA relative expression of experiment group was significant decreased (P < 0.05). CONCLUSION: Tashinone II A-sulfoacid-natrum can elevates the mechanical and thermal pain threshold through inhibiting the NF‑κB in neuropathic cancer pain rat.

Dolor neuropático oncológico en Chile: eficacia del programa alivio del dolor y cuidados paliativos por cáncer avanzado / Neuropathic cancer pain in Chile: efficacy of the pain relief for advanced cancer and palliative care program

Introducción: El cáncer cobra cada vez más relevancia en elperfil epidemiológico de los países desarrollados o en altas vías dedesarrollo, siendo el dolor el síntoma más frecuente y limitante,especialmente en estadíos avanzados. El dolor neuropático revisteespecial importancia en estos pacientes, debido a las diferenciasy dificultad de su manejo, su severidad y asociación a mayordeterioro en la calidad de vida. En Chile se ha estimado unaprevalencia 8,5% de dolor neuropático en pacientes ingresadosal Programa de Alivio del Dolor y Cuidados Paliativos por cánceravanzado. Este Programa ha sido evaluado exitosamente en elalivio del dolor previo al fallecimiento, sin distinción por tipo dedolor. El presente trabajo evalúa la eficacia de este programa enel alivio del dolor neuropático puro o combinado, y analiza losfactores asociados a su mejoría.Materiales y métodos: Estudio cuantitativo, observacional ylongitudinal sobre la mejoría del dolor, cuantificado según la EscalaVisual Análoga, obtenida entre el ingreso y el fallecimiento de lospacientes atendidos en Programa de Alivio del Dolor y CuidadosPaliativos por cáncer avanzado de Chile, entre los años 1995 a 2009.Se evaluó además, la asociación a variables clínicas y demográficas,mediante análisis de correspondencia y regresión logística, y serealizó un análisis del tiempo de sobrevida en el programa.Resultados: 8,5% (n=306) de los pacientes presentaron dolorneuropático puro o combinado. El 43,1% (n=132) correspondióa dolor somático-neuropático. Las principales localizacionesneoplásicas encontradas fueron: broncopulmonar, mama y cáncercerebral. 75,8% (n=232) vio disminuida su capacidad funcional.La mediana de sobrevida fue de 3 meses desde el ingreso...

Introduction: Every moment cancer takes more relevance on the epidemiologic profile of developed or in high developing countries, being pain the most frequent and limiting symptom, especially on advanced stages. Neuropathic pain is of special importance in this patients, because differences and difficulty on its management, its severity and higher association to a deterioration on life quality. In Chile, a prevalence of 8,5 percent on neuropathic pain has been estimated on patients admitted to the Pain Relief and Palliative Care by Advanced Cancer Program. This program has been evaluated as successful on pain relief before death, without differences by pain type. Our work aims to evaluate this program’s efficacy on relief of neuropathic pain (pure or combined), and to analyze factors associated to itsimprovement. Materials and methods: Quantitative, observational and longitudinal study of pain improvement, quantified by the Analog Visual Scale (AVS), obtained at admission and death of patients attended on the Pain Relief and Palliative Care by Advanced Cancer Program of Chile, between years 1995 to 2009. We also evaluated the association to clinical and demographic variables, through a correspondence analysis and logistic regression. We also analyzed survival in time in the program. Results: 8,5 percent (n=306) of patients presented pure or combined neuropathic pain. 43,1 percent (n=132) corresponded to somaticneuropathic pain. Main neoplastic localizations identifies were: bronchopulmonary, breast and brain cancer. 75,8 percent (n=232) had a detriment on its functional capacity...

Clinical therapeutic effect of Neurotropin combined with oxycodone hydrochloride for neuropathic cancer pain / 中国肿瘤临床

Objective:To investigate the clinical efficacy of Neurotropin combined with oxycodone hydrochloride in moderating the severe pain in neuropathic cancer pain (NCP) patients. Methods: NCP patients who received drug therapy with a visual analog scale (VAS) score of>4 were randomly divided into the placebo combined oxycodone group (group A) and Neurotropin combined oxy-codone group (group B). The VAS score, pain relief rate, frequency of pain outbreaks, average dose of oxycodone per day, and adverse drug reactions between the two groups were compared. Results:The VAS scores in groups A and B both had significant reduction after treatment (P<0.05), whereas the VAS score in group B after 14 days of treatment decreased more significantly than that in group A (P=0.03). The pain relief rate in group B patients 14 days after treatment was significantly higher than that in group A (P<0.001). The out-break pain in groups A and B 7 and 14 days after treatment significantly decreased, whereas the outbreak pain in group B was signifi-cantly lower than that in group A (P values were 0.07 and 0.07, respectively). The average dose of oxycodone per day in group B 14 days after treatment was lower than that in group A (P<0.001). Adverse reactions, such as nausea and vomiting, in group B were signifi-cantly less than those in group A (P<0.05). Conclusion:Neurotropin combined with oxycodone can effectively lower the NCP, average dose of oxycodone per day, and adverse reactions.